Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bibbinstruments AB, a Swedish medical device company, is dedicated to advancing the field of endoscopic technology. The company's primary focus lies in developing innovative biopsy instruments that facilitate early and accurate cancer diagnosis. Their groundbreaking products are engineered to enhance precision and efficiency in capturing tissue samples, which is pivotal in the effective identification and management of cancerous conditions. Operating within the healthcare and medical technology sectors, Bibbinstruments AB plays a significant role in improving diagnostic procedures and supporting oncological outcomes. With the rising global demand for better cancer diagnostic tools, the company holds a crucial position in the medical device market. Bibbinstruments AB's commitment to innovation serves to propel advancements in the endoscopic and diagnostic landscape, contributing to the overall enhancement of patient care and treatment efficacy.
kr 0.05
kr 0.00 (-4.17%)
Price from 5 days ago
The business is unprofitable at the operating level (-3658.35% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Negative free cash flow of -kr 18M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 477K
Net Income (TTM)
-kr 17M
▼ -15.0% YoY
Op. Margin
-3480.50%
ROIC
-35.11%
▼ -1.2pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 18M
▲ +1.0% YoY
Op. Cash Flow (TTM)
-kr 16M
▼ -11.7% YoY
Net Debt
-kr 6M
Net Cash Position
Cash & Equiv.
kr 6M
Continue Research
Bibbinstruments AB (BIBB.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Bibbinstruments AB scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Bibbinstruments AB scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -3,480.5% operating margin and a -35.1% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh BIBB.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.